Inducible clindamycin resistance among staphylococci isolated from burn patients

Libyan Journal of Medicine

Volumn 4, Issue 3, 2009, Pages 104-106

  Zorgani, A ^a,b   Shawerf, O ^a   Tawil, K ^a   El Turki, E ^a   Ghenghesh, K S ^a  

^a UNIVERSITY OF TRIPOLI   (Libyan Arab Jamahiriya)

^b Tripoli Medical Centre   (Libyan Arab Jamahiriya)

Author keywords

Burn patients; Inducible clindamycin resistance; Libya; Staphylococci

Indexed keywords

CLINDAMYCIN; METHICILLIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; S. AUREUS; SOFT TISSUE; TREATMENT FAILURE;

ENZYME INHIBITION;

CLINDAMYCIN; ERYTHROMYCIN;

ARTICLE; BURN INFECTION; CLINICAL ASSESSMENT; DISK DIFFUSION; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; TREATMENT FAILURE;

EID: 75149141755     PISSN: 19932820     EISSN: 18196357     Source Type: Journal    
DOI: 10.4176/090128     Document Type: Article

References (25)

1. Phillips LG, Heggers JP, Robson MC. Burn and trauma units as a source of MRSA. J. Burn Care Rehab. 1992; 13(Suppl 2):293-97.
2. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol. 2003; 41:4740-44.
3. Dumitrescu O, Boisset S, Badiou C, Bes M, BenitoY, Reverdy ME, et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother. 2007; 51:1515-19.
4. McGehee RF, Barrett FF, Finland F. Resistance of Staphylococcus aureus to lincomycin, clindamycin and erythromycin. Antimicrob Agents Chemother. 1968; 13:392-97.
5. Panagea S, Perry JD, Gould FK. Should clindamycin be used in treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother. 1999; 44:581-82.
6. Frank AL, Marcinak JF, Mahgat PD, Tjhio JT, Kelkar S, Schreckenberger PC, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2002; 21:530-34.
7. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. NCCLS M100-S14. NCCLS, Wayne, PA. 2004.
8. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis. 2003; 37:1257-60.
9. Azap OK, Arslan H, Timurkaynak F, Yapar G, Oruc E, Gagir U. Incidence of inducible clindamycin resistance in staphylococci: first results from Turkey. Clinical Microbiol Infect. 2005; 11:582-84.
10. Drinkovic D, Fuller ER, Shore KP, Holland DJ, Ellis-Pegler R. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother. 2001; 48:315-16.
11. Siberry GK, Tekle T, Carroll K, Dick J. 2003. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis. 2003; 37:1257-60.
12. Hamilton-Miller JMT, Shah S. Patterns of phenotypic resistance to the macrolide-lincosamide-ketolide-streptogramin group of antibiotics in staphylococci. J Antimicrob Chemother. 2000; 46:941-49.
13. Jennssen WD, Thakker-Varia S, Dubin DT, Weinstein MP. Prevalence of macrolides-lincosamides-streptogramin B resistance and erm gene classes among clinical strains of staphylococci and streptococci. Antimicrob Agents Chemother. 1987; 31:883-88.
14. Nicola FG, McDougal LK, Biddle JW, Tenover FC. Characterization of erythromycin-resistant isolates of Staphylococcus aureus recovered in the United States from 1958 through 1969. Antimicrob Agents Chemother. 1998; 42:3024-27.
15. Panagea S, Perry JD, Gould FK. Should clindamycin be used as treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother. 1999; 44:577-82.
16. Sanchez ML, Flint KK, Jones RN. Occurrence of macrolide-lincosamide- streptogramin resistance among staphylococcal clinical isolates at a university medical center. Diagn Microbiol Infect Dis. 1993; 16:205-13.
17. Sattler CA, Mason EO, Jr., Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J. 2002; 21:910-16.
18. Schreckenberger PC, Elizabeth I, Kathryn LR. Incidence of constitutive and inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci in a community and a teriatery care hospital. J Clin Microbiol. 2004; 42:2777-79.
19. Cowan SF, Steel KJ. Manual for identification of medical bacteria. 3rd ed. Cambridge University Press. 1993. pp. 140-43.
20. Clincal and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI M100-S15., CLSI, Wayne, PA. 2005.
21. Jorgensen JH, Crawford SA, McElmeel ML, Fiebelkorn KR. Detection of inducible clindamycin resistance of staphylococci in conjunction with performance of automated broth susceptibility testing. J Clin Microbiol. 2004; 42:1800-2.
22. Farrell D, Shackloth J, Cossins L, Quintana A, Hogan P. High prevalence of inducible clindamycin resistance among community-associated methicillin resistant Staphylococcus aureus in Europe. Int J Antimicrob Agents. 2007; 29(Suppl):S520.
23. Kader AA, Kumar A, Krishna A. Induction of clindamycin resistance in erythromycin-resistant, clindamycin-susceptible and methicillin-resistant clinical staphylococcal isolates. Saudi Med J. 2005; 26:1914-17.
24. Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarditis. Clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin. Am J Med. 1976; 60:419-25.
25. Levin TP, Suh B, Axelrod P, Truant AL, Fekete T. Potential clindamycin resistance in clindamycin-susceptible, erythromycin-resistant Staphylococcus aureus: report of a clinical failure. Antimicrob Agents Chemother. 2005; 49:1222-24.